BIONATURIS

Trading sesion


30/11/2016 Close

3.0000

Last price


15.27 mill. €

Capitalisation

0.00

Dif.(%)


-16.67

% Year 2016

Last Trade

Last

3.0000

Ref.

3.0000

Dif.(%)

0.00

Volume (Shares)

1,750

Turnover (€x1000)

5.19

Security

Security name

BIONATURIS (BIOORGANIC RESEARCH SERV.)

Ticker

BNT

ISIN

ES0184980003

NIF

A-11811163

Capital Admitted

254.508,95 Euros

Shares Admitted

5.090.179

Nominal

0,05 Euros

Trading

Continuo

Liquidity Provider

GVC GAESCO BEKA, S.V., S.A.

Registered Advisor

DCM ASESORES Dirección y Consultoría de Mercados, S.L.

Auditor

PAEZ & SERRANO AUDITORIES, S.L.U.

Address

AV DESARROLLO TECNOLOGICO 11, JEREZ DE LA FRONTERA

Contact

ir@bionaturis.com

Historical Summary

 20122013201420152016 until 2/12

Capital Admitted (thousands of euros)

210210232232255

Shares (x 1,000)

4,1924,1924,6334,6335,090

Period Close Price (euros)

2.26004.75007.90003.60003.0000

Period Last Price (euros)

2.26004.75007.90003.60003.0000

Period High Price (euros)

2.40005.800013.98008.20005.2300

Period Low Price (euros)

2.10001.58003.53003.59002.6500

Capitalisation (thousands of euros)

9,47319,91136,60116,67915,271

Volume (thousands of shares)

603103,3952,136401

Turnover (thousands of euros)

1341,06824,84911,9571,532

Company Profile

Bionaturis -established in Cadiz in 2005- is a biopharmaceutical company developing and producing biomedical products for the pharmaceutical and veterinarian sectors. Bionaturis specializes in the prevention and treatment of niche diseases, such as orphan diseases.

As value proposition Bionaturis has chosen Nature as an optimized source for the production of biopharmaceuticals, substituting the traditional industrial cumbersome steel reactors for single use, disposable and naturally occurring individual reactors: FLYLIFEÒ.  FLYLIFEÒ makes use of natural resources to achieve and indeed surpass the productive capacity of traditional industry standards but utilizing up to ten-fold less space and fifteen-fold less investment.  Amongst others, in niche markets where currently there is no solution, these competitive advantages provide a profitable solution and gives renewed hope to millions of worldwide patients. 

Its mission is to position itself as leader within the field of new platforms for production of biopharmaceuticals for veterinary and human use, and convert itself into a worldwide reference entity for the development of orphan drugs.

To complete its mission Bionaturis has chosen a mixed business model which combines short-term income through R+D services and production for third parties (BNT-CDMO), this in combination with co-development of biopharmaceuticals, which generates incomes through licensing royalties and the completion of milestones in the medium and long term (BNT-PRODUCTS).

 Year on year Bionaturis has increased the portfolio of international patents, either developed internally or acquired through license.  

Relevant Facts and Notices

Financial Reports

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Copyright © Bolsas y Mercados Españoles 2016. All rights reserved. Disclaimer // Legal Disclaimer // Suppliers payment period